



BSW Formulary Update – January 2023

New and Updated Shared Care Agreements (SCA) and Prescribing Guidance

- **Updated** – Our existing SCAs for buccal midazolam have been reviewed and can be found here [Shared Care Agreements - Medicines \(bswtogether.org.uk\)](https://www.bswtogether.org.uk). Updates reflect the change in Epistatus® licence (now licensed in children aged over 3 months; previously use in under 10years was outside product licence). **Please note that Buccolam® brand remains the first-line brand of choice across BSW** for prolonged seizures and prevention of status epilepticus.
- **New** – [Asthma Inhaler Prescribing Guideline in Adults](#). This new local guideline has been developed with specialist respiratory input from colleagues at RUH/GWH/SFT and BSW community based respiratory nurses. The guideline states BSWFormulary recommended, first choice inhalers. The intention is to support the choice of treatment for new patients, or patients needing stepping up or down. For most patients requiring a new or changed inhaler, one of the first line inhaler choices should be prescribed, using the brand names in the guideline to minimise the risk of dispensing errors. Patients currently using alternative inhalers should only be switched if clinically appropriate and the patient has an asthma review. Guideline also includes information on greener inhaler prescribing (carbon footprint information).

New additions to BSWformulary

- [Lacosamide](#) 200mg/20ml solution for infusion added for use in secondary care. **Red** TLS
- [Stiripentol](#) powder sachets 250mg & 500mg and capsules 100mg, 250mg & 500mg added for Dravet syndrome under guidance of tertiary epilepsy service and in line with [NG217](#). **Red** TLS (note TLS under review; shared care agreement in development).

Other BSWformulary updates

- [Deferasirox](#) – Use extended to include locally commissioned off-label use in patients undergoing haematopoietic stem cell transplantation and patients with low-risk myelodysplastic syndrome. **Red** TLS
- [Acetylcholine intra-ocular irrigation](#) Use extended to include (off-label) use in cardiac cath lab, only in line with approved Trust protocol. **Red** TLS
- General information on prescribing ACBS products for patients with phenylketonuria including useful links and contact details for dietetics prescribing support team included in [nutrition chapter](#).
- [Oral acetazolamide](#) - indications and traffic light status aligned for BSW: **Amber** for glaucoma (licensed indication); **Amber** for idiopathic intracranial hypertension (not licensed for this indication); Private prescription only for altitude sickness (not licensed for this indication).
- Anticoagulants and blood products: [Prothrombin complex concentrate](#) aligned with **Red** TLS; [Fondaparinux injection](#) aligned with **Red** TLS; [Danaparoid injection](#) moved to non-formulary.



- [Bismuth subsalicylate](#) 262.5mg chewable tablets. Aligned with **Green** TLS; only for FP10 prescribing as part of *H.Pylori* eradication therapy. OTC purchase for other indications.

What the BSW CCG formulary team are currently working on

- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. As a result, amiodarone and valproate have been selected for implementation.
- Working with colleagues on the BNSSG/BSW Wound Care Formulary Group to review choice and procurement of dressings and woundcare products used by nursing teams across BSW.
- Reviewing local guidelines for blood glucose monitoring.
- Working with ophthalmology colleagues across BSW to update local guidance on treatment of dry eye and to align historical formulary differences and traffic light statuses of ophthalmic products.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net